Observational studyClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024
Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions.
Observational study in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03646227 (Multi-Drug Resistant Organism Network - MDRO Network), which is not on this map. Cited by 68 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-Drug Resistant Organism Network - MDRO Network
Who cites it
68 citing papers in PubMed, 3 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Comparative effectiveness of antimicrobial regimens for pneumonia caused by drug-resistant Acinetobacter baumannii: a network meta-analysis including cefiderocol and inhaled therapies.BMC infectious diseases · 2026Pooled it
- Global trends in carbapenem-resistant gram-negative bacteria research (2020-2025): a bibliometric analysis and systematic review.Frontiers in cellular and infection microbiology · 2025Pooled it
- Factors affecting the effectiveness and safety of colistin in treating drug-resistant gram-negative bacterial infections: a meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Characterization ofAntimicrobial agents and chemotherapy · 2024Trial
- Comorbidities and Patient Outcomes in Carbapenem-Resistant Gram-negative Bacterial Infections.Open forum infectious diseases · 2026Article
- Multiplex RPA-CRISPR/Cas12a Assay for Rapid Detection of Class D OXA-Type Carbapenem-ResistantBiosensors · 2026Article
- Distinct molecular epidemiology and outcomes of carbapenem-resistant gram-negative infections in Lebanon: insights from the MDRO network.BMC infectious diseases · 2026Article
- Integrated clinical and genomic characterization ofJournal of medical microbiology · 2026Article
- Antimicrobial Resistance and Clinical Outcome Among Hospitalized Bacterial Pneumonia: A Retrospective Cohort Study in Indonesian Tertiary Hospital.Antibiotics (Basel, Switzerland) · 2026Article
- Mobilization of the AbGRI4 resistance island inMicrobiology spectrum · 2026Article
- Multidrug-resistant Acinetobacter spp. bloodstream infections in hematologic patients: clinical characteristics, genomic features, and eravacycline-based combination therapy.BMC infectious diseases · 2026Article
- Genomic and phenotypic characterization of carbapenem-resistant Acinetobacter baumannii isolates from patients and trolleys and their potential connections in an intensive care unit.BMC microbiology · 2026Observational
- Article
- Factors Associated with Short-Term Clinical Outcomes in ICU Patients with Carbapenem-ResistantJournal of clinical medicine · 2026Article
- Sulbactam-Durlobactam for Carbapenem-ResistantPathogens (Basel, Switzerland) · 2026Review
- Comparative genomic surveillance of carbapenem-resistantMicrobiology spectrum · 2026Article
- Sulbactam-Durlobactam in the Treatment of Bloodstream Infection Due to Carbapenem-ResistantJournal of clinical medicine · 2026Review
- Plumbagin Disrupts Biofilm Integrity and Resistance Gene Expression in Carbapenem-ResistantJournal of microbiology and biotechnology · 2026Article
- Clonal Dynamics and Antimicrobial Resistance of Bloodstream Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Genetic basis of cefiderocol resistance inMicrobiology spectrum · 2026Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors at 20 institutions in 11 countries.
Funding
Abstract
backgroundCarbapenem-resistant Acinetobacter baumannii (CRAb) is 1 of the most problematic antimicrobial-resistant bacteria. We sought to elucidate the international epidemiology and clinical impact of CRAb.
methodsIn a prospective observational cohort study, 842 hospitalized patients with a clinical CRAb culture were enrolled at 46 hospitals in five global regions between 2017 and 2019. The primary outcome was all-cause mortality at 30 days from the index culture. The strains underwent whole-genome analysis.
resultsOf 842 cases, 536 (64%) represented infection. By 30 days, 128 (24%) of the infected patients died, ranging from 1 (6%) of 18 in Australia-Singapore to 54 (25%) of 216 in the United States and 24 (49%) of 49 in South-Central America, whereas 42 (14%) of non-infected patients died. Bacteremia was associated with a higher risk of death compared with other types of infection (40 [42%] of 96 vs 88 [20%] of 440). In a multivariable logistic regression analysis, bloodstream infection and higher age-adjusted Charlson comorbidity index were independently associated with 30-day mortality. Clonal group 2 (CG2) strains predominated except in South-Central America, ranging from 216 (59%) of 369 in the United States to 282 (97%) of 291 in China. Acquired carbapenemase genes were carried by 769 (91%) of the 842 isolates. CG2 strains were significantly associated with higher levels of meropenem resistance, yet non-CG2 cases were over-represented among the deaths compared with CG2 cases.
conclusionsCRAb infection types and clinical outcomes differed significantly across regions. Although CG2 strains remained predominant, non-CG2 strains were associated with higher mortality. Clinical Trials Registration. NCT03646227.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.